cormedix shares were down sharply ahead of the bell thursday after the biopharmaceutical company priced a 40 million public offering of stock and warrants to help fund commercialization efforts and research and development in premarket trading the shares were 21 lower after ending the previous session at 507 up 20 so far this year cormedix which is focused on developing and commercializing therapeutic products for the prevention and treatment of lifethreatening diseases and conditions late wednesday said it offer of 75 million of its shares priced at 4 apiece and in lieu of stock to certain investors prefunded warrants to buy up to 25 million shares in all priced at 3999 each the underwriters of the offering have a 30day option to buy up to an additional 15 million shares cormedix said the offering is expected to close on or about july 3